T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine

A practical booster vaccine is urgently needed to control the coronavirus disease (COVID-19) pandemic. We have previously reported the safety and immunogenicity of a fractional intradermal booster, using the BNT162b2 mRNA vaccine in healthy volunteers who had completed two doses of inactivated SARS-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sophonmanee, Ratchanon, Ongarj, Jomkwan, Seeyankem, Bunya, Seepathomnarong, Purilap, Intapiboon, Porntip, Surasombatpattana, Smonrapat, Uppanisakorn, Supattra, Sangsupawanich, Pasuree, Chusri, Sarunyou, Pinpathomrat, Nawamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501140/
https://www.ncbi.nlm.nih.gov/pubmed/36146571
http://dx.doi.org/10.3390/vaccines10091494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501140/
https://www.ncbi.nlm.nih.gov/pubmed/36146571
http://dx.doi.org/10.3390/vaccines10091494

Ejemplares similares